lack predict valu islet cell antibodi insulin antibodi hla-dr phenotyp remiss cyclosporin-tr iddm patient canadian-european random control trial group effect immunosuppress humor immun respons autoantigen insulin predict valu islet cell cytoplasm antibodi ica insulin antibodi ia hla-dr phenotyp remiss immunosuppress prospect double-blind trial cyclosporin administr insulin-depend diabet iddm patient hla-dr phenotyp hemoglobin studi entri insulin requir glucagon-stimul c-peptid ica ia entri mo follow-up cyclosporin therapi signific suppress preval serum concentr ica ia cyclosporin-tr iddm patient ica+ studi entri level c-peptid mo studi increas beta-cel function frequenc insulin-fre remiss mo ica IA statu entri cyclosporin-insulin-fre remiss preval insulin-fre remiss beta-cel function mo studi signific decrement titer total disappear ica preval durat non-insulin-requir remiss c-peptid valu correl serum level ica ia entri beta-cel function mo follow-up 